Usefulness of hepatitis C virus RNA counts by second generation HCV bDNA-probe in chronic hepatitis C based on the HCV genotype

Kobayashi, Mariko; Kumada, Hiromitsu; Arase, Yasuji; Chayama, Kazuaki; Kobayashi, Masahiro; Tsubota, Akihito; Koida, Isao; Saitoh, Satoshi; Suzuki, Yosiyuki; Murashima, Naoya; Ikeda, Kenji; Miyano, Yukiko; Mizoshita, Kaori; Matsuda, Marie; Koike, Hiromi; Hashimoto, Michie; Kobayashi, M; Kumada, H; Arase, Y; Chayama, K
April 1998
Journal of Gastroenterology;1998, Vol. 33 Issue 2, p223
Academic Journal
journal article
Detection of hepatitis C virus (HCV) RNA by a second generation (ver 2) HCV bDNA-probe method (bDNA-probe) was compared with detection by the first generation (ver 1) assay. The two assays were performed simultaneously with the same serum samples of HCV genotypes 1b, 2a, 2b, 3a, and 3b. The positive rates with ver 1 were 82% for HCV genotype 1b (type 1b), 57.6% for HCV genotype 2a (type 2a), 75.0% for HCV genotype 2b (type 2b), 55.6% for HCV genotype 3a (type 3a), and 93.8% for HCV genotype 3b (type 3b). The positive rates with ver 2 were 95.0% for type 1b, 93.9% for type 2a, 83.3% for type 2b, 100% for type 3a, and 93.8% for type 3b. With Fisher's exact test, the detection rate for type 2a was significantly higher (P = 0.001) with ver 2 than with ver 1. We obtained regression lines using the HCV counts measured by bDNA-probe on the y axis and the HCV counts obtained by an HCV reverse transcriptase (RT)-competitive polymerase chain reaction method (competitive PCR) on the x axis. The gradients for types 1b, 2a, and 3b were greater with ver 2 compared to ver 1. The gradients for types 2a and 3b were the highest: for type 2a, y = 0.135x + 0.6 with ver 1 and y = 0.248x + 0.1 with ver 2; for type 3b, y = 0.366x + 0.1 with ver 1 and y = 0.727x + 0.3 for ver 2. In addition, HCV-RNA counts for all the genotypes tested in this study were significantly higher with ver 2 than with ver 1. Hence, we conclude that ver 2 of the bDNA-probe measures HCV-RNA counts closer to those obtained with competitive PCR than the ver 1 assay.


Related Articles

  • Hepatitis C Virus-Related Hepatic Myelopathy After Treatment With Sofosbuvir and Ribavirin: A Case Report. di Biase, Lazzaro; Picillo, Marina; Eliza Freitas, Maria; Bui, Esther; Fasano, Alfonso; Freitas, Maria Eliza // Annals of Internal Medicine;3/7/2017, Vol. 166 Issue 5, p379 

    A case study of a 61 years old patient suffering with hepatitis C virus (HCV) is presented. It presents information on the impact of hepatic myelopathy complications on liver dysfunction of the patient with HCV. It also includes information on the treatment of the patient with sofosbuvir and...

  • Antiviral activity of amantadine in elderly patients with chronic hepatitis C. Torre, F.; Campo, N.; Giusto, R.; Ansaldi, F.; Icardi, G. C.; Picciotto, A. // Gerontology;2001, Vol. 47 Issue 6, p330 

    Background: Hepatitis C virus (HCV) infection is a worldwide problem of public health. Epidemiological studies have shown a significant higher prevalence of infection in the elderly. Amantadine is an antiviral agent active against the influenza A virus that has been used in cases of...

  • Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. McMahan, Rachel H.; Golden-Mason, Lucy; Nishimura, Michael I.; McMahon, Brian J.; Kemper, Michael; Allen, Todd M.; Gretch, David R.; Rosen, Hugo R. // Journal of Clinical Investigation;Dec2010, Vol. 120 Issue 12, p4546 

    Having successfully developed mechanisms to evade immune clearance, hepatitis C virus (HCV) establishes persistent infection in approximately 75%-80% of patients. In these individuals, the function of HCV-specific CD8+ T cells is impaired by ligation of inhibitory receptors, the repertoire of...

  • Chemokine antagonism in chronic hepatitis C virus infection. Charles, Edgar D.; Dustin, Lynn B. // Journal of Clinical Investigation;Jan2011, Vol. 121 Issue 1, p25 

    Immune responses to hepatitis C virus (HCV) fail to clear the virus in most individuals. Why patients who are less likely to clear HCV infection have high plasma levels of CXCL10 (also known as IP-10), a chemokine that directs T cells to sites of infection, has long been unclear. In this issue...

  • Determinants of the quantity of hepatitis C virus RNA. Thomas, David L.; Astemborski, Jacquie; Vlahoy, David; Strathdee, Steffanie A.; Ray, Stuart C.; Nelson, Kenrad E.; Galai, Noya; Nolt, Karen R.; Laeyendecker, Oliver; Todd, John A.; Thomas, D L; Astemborski, J; Vlahov, D; Strathdee, S A; Ray, S C; Nelson, K E; Galai, N; Nolt, K R; Laeyendecker, O; Todd, J A // Journal of Infectious Diseases;3/1/2000, Vol. 181 Issue 3, p844 

    To test the hypothesis that person-to-person variability in blood levels of hepatitis C virus (HCV) RNA can be explained, the quantity of HCV RNA was assessed in 969 persons who acquired HCV infection in the context of injection drug use. Serum HCV RNA levels ranged from 200,000 to >120 million...

  • Pneumocystis jirovecii dihydropteroate synthase genotypes in immunocompetent infants and immunosuppressed adults, Amiens, France. Totet, Anne; Latouche, Sophie; Lacube, Philippe; Pautard, Jean-Claude; Jounieaux, Vincent; Raccurt, Christian; Roux, Patricia; Nevez, Gilles // Emerging Infectious Diseases;Apr2004, Vol. 10 Issue 4, p667 

    To date, investigations of Pneumocystis jirovecii circulation in the human reservoir through the dihydropteroate synthase (DHPS) locus analysis have only been conducted by examining PP jirovecii isolates from immunosuppressed patients with Pneumocystis pneumonia (PCP). Our study identifies PP...

  • A case of late onset sporadic Parkinson's disease with an A53T mutation in alpha-synuclein. Michell, A. W.; Barker, R. A.; Raha-Chowdhury, R.; Raha, S. K. // Journal of Neurology, Neurosurgery & Psychiatry;Apr2005, Vol. 76 Issue 4, p596 

    Presents a letter to the editor about Parkinson's disease, appeared in the April 2005 issue of the "Journal of Neurology, Neurosurgery & Psychiatry."

  • Chronic Hepatitis C Virus Infection and the Proinflammatory Effects of Injection Drug Use. Markowitz, Martin; Deren, Sherry; Cleland, Charles; La Mar, Melissa; Silva, Evelyn; Batista, Pedro; St. Bernard, Leslie; Gettie, Natanya; Rodriguez, Kristina; Evering, Teresa H.; Haekyung Lee; Mehandru, Saurabh; Lee, Haekyung // Journal of Infectious Diseases;11/1/2016, Vol. 214 Issue 9, p1376 

    Background:  Chronic inflammation, as defined by persistent immune activation, is associated with adverse clinical outcomes. People who inject drugs (PWID) have evidence of persistent immune activation. Here, in a cohort of PWID with or without hepatitis C virus (HCV)...

  • CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. Spurdle, Amanda B.; Hopper, John L.; Spurdle, A B; Hopper, J L; Dite, G S; Chen, X; Cui, J; McCredie, M R; Giles, G G; Southey, M C; Venter, D J; Easton, D F; Chenevix-Trench, G // JNCI: Journal of the National Cancer Institute;10/18/2000, Vol. 92 Issue 20, p1674 

    Background: The cytochrome P450c17alpha enzyme functions in the steroid biosynthesis pathway, and altered endogenous steroid hormone levels have been reported to be associated with a T to C polymorphism in the 5' promoter region of the CYP17 gene. Because steroid hormone exposure is...

  • Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Bard, J. Dien; Gelebart, P.; Anand, M.; Amin, H. M.; Lai, R. // Leukemia (08876924);Aug2008, Vol. 22 Issue 8, p1595 

    One of the characteristic features of anaplastic lymphoma kinase (ALK)(+), anaplastic large cell lymphoma (ALK(+)ALCL) is the constitutive activation of signal transducers and activators of transcription-3 (STAT3), a defect believed to be important for the pathogenesis of these tumors. In this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics